[{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"38aae3c4-f386-4a60-a95e-c6b46ee44656","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656248","created_at":"2022-12-19T14:58:46.031Z","updated_at":"2025-02-25T14:41:44.924Z","phase":"Phase 2","brief_title":"Study of CPX-351 (VYXEOS) in Individuals \u003c 22 Years With Secondary Myeloid Neoplasms","source_id_and_acronym":"NCT05656248","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26","pipe":"","alterations":" ","tags":["TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-14"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"aed6a81b-c738-4d5c-8f36-6106ea988728","acronym":"","url":"https://clinicaltrials.gov/study/NCT06458257","created_at":"2024-06-15T04:06:59.412Z","updated_at":"2024-07-02T16:34:26.336Z","phase":"","brief_title":"The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia","source_id_and_acronym":"NCT06458257","lead_sponsor":"Ruijin Hospital","biomarkers":" CEBPA","pipe":"","alterations":" ","tags":["CEBPA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-13"},{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"fe2e9c02-b568-4273-9f6b-89146f4af44d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756962","created_at":"2021-01-18T13:30:57.647Z","updated_at":"2024-07-02T16:35:12.037Z","phase":"Phase 2","brief_title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","source_id_and_acronym":"NCT02756962","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation","tags":["FLT3 • NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 07/06/2016","start_date":" 07/06/2016","primary_txt":" Primary completion: 07/31/2033","primary_completion_date":" 07/31/2033","study_txt":" Completion: 07/31/2033","study_completion_date":" 07/31/2033","last_update_posted":"2024-04-02"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"ffb94954-f1c1-4247-b33c-267b8f6f3014","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231851","created_at":"2021-01-18T20:35:11.661Z","updated_at":"2024-07-02T16:35:20.841Z","phase":"Phase 2","brief_title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","source_id_and_acronym":"NCT04231851","lead_sponsor":"University of California, Irvine","biomarkers":" NPM1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-02-05"},{"id":"1c457901-9a43-4dcc-9740-e44b1b37ea65","acronym":"NCI-2018-03465","url":"https://clinicaltrials.gov/study/NCT03862157","created_at":"2021-01-18T19:03:08.762Z","updated_at":"2024-07-02T16:35:23.829Z","phase":"Phase 1/2","brief_title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT03862157 - NCI-2018-03465","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA","pipe":" | ","alterations":" NPM1 mutation • CEBPA mutation • PDGFRA rearrangement","tags":["ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CEBPA mutation • PDGFRA rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/27/2019","start_date":" 02/27/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"a4bb1a34-471b-4555-af24-fb6959389923","acronym":"OUTREACH2","url":"https://clinicaltrials.gov/study/NCT04710641","created_at":"2021-01-19T20:52:22.729Z","updated_at":"2024-07-02T16:35:28.099Z","phase":"Phase 2","brief_title":"Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone","source_id_and_acronym":"NCT04710641 - OUTREACH2","lead_sponsor":"Mina Alpha Limited","biomarkers":" CEBPA","pipe":"","alterations":" ","tags":["CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • MTL-CEBPA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-11-27"},{"id":"ec691ea0-9e7c-4022-8073-c784470d60c2","acronym":"OUTREACH","url":"https://clinicaltrials.gov/study/NCT02716012","created_at":"2021-01-18T13:16:58.176Z","updated_at":"2024-07-02T16:35:28.063Z","phase":"Phase 1","brief_title":"First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer","source_id_and_acronym":"NCT02716012 - OUTREACH","lead_sponsor":"Mina Alpha Limited","biomarkers":" CEBPA","pipe":"","alterations":" ","tags":["CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • MTL-CEBPA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-27"},{"id":"7d36623f-54df-47be-a4e4-1dee851f8906","acronym":"COALA","url":"https://clinicaltrials.gov/study/NCT05499611","created_at":"2022-11-08T19:21:31.726Z","updated_at":"2024-07-02T16:35:31.379Z","phase":"","brief_title":"Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia","source_id_and_acronym":"NCT05499611 - COALA","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" TP53 • NPM1 • RUNX1 • ASXL1 • CEBPA","pipe":" | ","alterations":" Chr del(5q) • Chr t(9;11)","tags":["TP53 • NPM1 • RUNX1 • ASXL1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q) • Chr t(9;11)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/27/2023","start_date":" 01/27/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-10-27"},{"id":"859b9a56-0db0-49fc-bcaf-d9e45201f632","acronym":"","url":"https://clinicaltrials.gov/study/NCT04415008","created_at":"2021-01-18T21:16:51.688Z","updated_at":"2024-07-02T16:35:34.633Z","phase":"Phase 2","brief_title":"Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT04415008","lead_sponsor":"wang, jianxiang","biomarkers":" CEBPA","pipe":" | ","alterations":" CEBPA mutation","tags":["CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-05"},{"id":"b35dfb7f-729a-42fd-91e4-c017d8f20df6","acronym":"TIMEPOINT","url":"https://clinicaltrials.gov/study/NCT04105335","created_at":"2021-01-18T20:04:41.504Z","updated_at":"2024-07-02T16:35:46.561Z","phase":"Phase 1","brief_title":"A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)","source_id_and_acronym":"NCT04105335 - TIMEPOINT","lead_sponsor":"Mina Alpha Limited","biomarkers":" PD-L1 • CEBPA","pipe":"","alterations":" ","tags":["PD-L1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MTL-CEBPA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-06-05"},{"id":"4636ef7a-95bb-4522-a60b-2fd02b36b883","acronym":"","url":"https://clinicaltrials.gov/study/NCT04173585","created_at":"2021-01-18T20:21:37.711Z","updated_at":"2024-07-02T16:35:52.203Z","phase":"Phase 2","brief_title":"TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib","source_id_and_acronym":"NCT04173585","lead_sponsor":"University Hospital Heidelberg","biomarkers":" FLT3 • CEBPA","pipe":" | ","alterations":" CEBPA mutation","tags":["FLT3 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2023-03-27"},{"id":"e1c7ba24-44af-4b89-9a62-1500c297696f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02722668","created_at":"2021-01-18T13:19:16.731Z","updated_at":"2024-07-02T16:35:54.803Z","phase":"Phase 2","brief_title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","source_id_and_acronym":"NCT02722668","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2023-02-24"},{"id":"89d88dc2-c1e4-4a45-b7f0-527d8736891a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01597778","created_at":"2021-01-18T06:49:49.857Z","updated_at":"2024-07-02T16:36:19.976Z","phase":"Phase 3","brief_title":"Double Cord Versus Haploidentical (BMT CTN 1101)","source_id_and_acronym":"NCT01597778","lead_sponsor":"Medical College of Wisconsin","biomarkers":" NPM1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 368","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 09/11/2020","primary_completion_date":" 09/11/2020","study_txt":" Completion: 09/11/2020","study_completion_date":" 09/11/2020","last_update_posted":"2021-12-01"},{"id":"8685c132-e923-4108-8205-2e1925660d94","acronym":"PCR-LMA","url":"https://clinicaltrials.gov/study/NCT04446741","created_at":"2021-01-18T21:23:54.145Z","updated_at":"2024-07-02T16:36:24.804Z","phase":"","brief_title":"Molecular Diagnostic Platform for AML","source_id_and_acronym":"NCT04446741 - PCR-LMA","lead_sponsor":"PETHEMA Foundation","biomarkers":" TP53 • FLT3 • IDH2 • NPM1 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • BRINP3 • SMC1A","pipe":" | ","alterations":" NPM1 mutation • U2AF1 mutation • CEBPA mutation","tags":["TP53 • FLT3 • IDH2 • NPM1 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • BRINP3 • SMC1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • U2AF1 mutation • CEBPA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2021-09-06"},{"id":"73e97b9d-0254-43f8-997d-ea880735e4cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311815","created_at":"2021-01-18T16:21:28.250Z","updated_at":"2024-07-02T16:36:34.554Z","phase":"","brief_title":"Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.","source_id_and_acronym":"NCT03311815","lead_sponsor":"PETHEMA Foundation","biomarkers":" KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2","pipe":" | ","alterations":" U2AF1 mutation","tags":["KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e U2AF1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 900","initiation":"Initiation: 10/06/2017","start_date":" 10/06/2017","primary_txt":" Primary completion: 10/15/2019","primary_completion_date":" 10/15/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2021-02-16"},{"id":"dfaad6a0-3889-459b-9507-38a2e33f855a","acronym":"FLAM","url":"https://clinicaltrials.gov/study/NCT03547258","created_at":"2021-01-18T17:27:52.639Z","updated_at":"2024-07-02T16:36:45.759Z","phase":"","brief_title":"Italian Non-Interventional Study of FLT3 Mutated AML Patients","source_id_and_acronym":"NCT03547258 - FLAM","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" TP53 • FLT3 • IDH2 • WT1 • CEBPA","pipe":" | ","alterations":" FLT3 mutation • FLT3 positive","tags":["TP53 • FLT3 • IDH2 • WT1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 positive"],"overall_status":"Unknown status","enrollment":" Enrollment 800","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2020-04-21"},{"id":"7fe340c9-513c-406f-b823-d137d2a40da4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00553202","created_at":"2021-01-18T02:00:55.280Z","updated_at":"2024-07-02T16:36:45.945Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia","source_id_and_acronym":"NCT00553202","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 158","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 03/31/2020","study_completion_date":" 03/31/2020","last_update_posted":"2020-04-16"},{"id":"8581491d-374e-47d8-8cf7-20ff1d417401","acronym":"","url":"https://clinicaltrials.gov/study/NCT02017457","created_at":"2021-01-18T09:13:52.590Z","updated_at":"2025-02-25T14:34:27.169Z","phase":"Phase 2","brief_title":"Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.","source_id_and_acronym":"NCT02017457","lead_sponsor":"Carlos Graux, MD, PhD","biomarkers":" NPM1 • WT1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL-PTD","tags":["NPM1 • WT1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL-PTD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2019-12-10"}]